Karen M Tordjman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6873056/publications.pdf

Version: 2024-02-01

18 papers	710 citations	933447 10 h-index	996975 15 g-index
18	18	18	861 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 2504.	2.4	2
2	Low-Dose Cyproterone Acetate Treatment for Transgender Women. Journal of Sexual Medicine, 2021, 18, 1292-1298.	0.6	11
3	Impaired aldosterone response to ACTH without hypoaldosteronism: An unrecognized secretory pattern in search of clinical implications. Clinical Endocrinology, 2021, , .	2.4	O
4	Revisiting Cushing Syndrome, Milder Forms Are Now a Common Occurrence: A Single-Center Cohort of 76 Subjects. Endocrine Practice, 2021, 27, 859-865.	2.1	3
5	SUN-042 Low Dose Cyproterone Acetate for the Treatment of Transgender Women - a Retrospective Study. Journal of the Endocrine Society, 2020, 4, .	0.2	1
6	Scarless Neck Feminization: Transoral Transvestibular Approach Chondrolaryngoplasty. Facial Plastic Surgery and Aesthetic Medicine, 2020, 22, 172-180.	0.9	23
7	Re: "Effects of Radioactive Iodine Therapy on Ovarian Reserve: A Prospective Pilot Study―by Evranos <i>et al</i> . (<i>Thyroid</i> 2018;28:1702–1707). Thyroid, 2019, 29, 453-453.	4.5	0
8	Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: a Possible Stem Cell Phenomenon. Endocrine Pathology, 2019, 30, 74-80.	9.0	25
9	OR11-3 Evidence for Preserved Ovarian Reserve in Transgender Men Receiving Testosterone Therapy: Anti-Mullerian Hormone Serum Levels Decrease Modestly after One Year of Treatment. Journal of the Endocrine Society, 2019, 3, .	0.2	0
10	A Single Radioactive Iodine Treatment Has a Deleterious Effect on Ovarian Reserve in Women with Thyroid Cancer: Results of a Prospective Pilot Study. Thyroid, 2018, 28, 522-527.	4.5	35
11	Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors. Pituitary, 2016, 19, 322-331.	2.9	23
12	Exposure to endocrine disrupting chemicals among residents of a rural vegetarian/vegan community. Environment International, 2016, 97, 68-75.	10.0	16
13	The Proatherogenic Effect of Chronic Nitric Oxide Synthesis Inhibition in ApoE-Null Mice Is Dependent on the Presence of PPAR <i>α</i> . PPAR Research, 2014, 2014, 1-10.	2.4	5
14	Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. European Journal of Endocrinology, 2010, 162, 925-933.	3.7	77
15	Absence of Peroxisome Proliferator-Activated Receptor-α Abolishes Hypertension and Attenuates Atherosclerosis in the Tsukuba Hypertensive Mouse. Hypertension, 2007, 50, 945-951.	2.7	34
16	Characterization of normocalcemic primary hyperparathyroidism. American Journal of Medicine, 2004, 117, 861-863.	1.5	105
17	Lowâ€dose (1 μg) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo–pituitary–adrenal axis function: sensitivity, specificity and accuracy in comparison with the highâ€dose (250 μg) test. Clinical Endocrinology, 2000, 52, 633-640.	2.4	159
18	Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clinical Endocrinology, 1998, 48, 547-553.	2.4	191